Rockwell Automation, Inc.
$50.66B- Market cap
- $47.90B
- Debt
- +$3.22B
- Cash
- −$468.00M
Capital structure 94% equity / 6% debt · EV / Revenue 6.07x · EV proxy / EBITDA proxy 24.98x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: ROK stock price vs AVTX: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AVTX's multiple
Needs AVTX P/E.
Implied fair value · at ROK's multiple
Needs Annual EPS is negative.
Snapshot Sep 11, 2026, 1:27 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
11 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Capital structure 94% equity / 6% debt · EV / Revenue 6.07x · EV proxy / EBITDA proxy 24.98x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Rockwell Automation, Inc. · implied price per share
Bear
$103.76
Base
$128.85
Bull
$162.70
AVALO THERAPEUTICS, INC. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
EMERSON ELECTRIC CO
ROK vs EMR
Parker-Hannifin Corp
ROK vs PH
DANAHER CORP /DE/
ROK vs DHR
TERADYNE, INC
ROK vs TER
Eaton Corp plc
ROK vs ETN
COGNEX CORP
ROK vs CGNX
CytomX Therapeutics, Inc.
ROK vs CTMX
IDEAYA Biosciences, Inc.
ROK vs IDYA
Ocugen, Inc.
ROK vs OCGN
CLOVER HEALTH INVESTMENTS, CORP. /DE
ROK vs CLOV
Citius Pharmaceuticals, Inc.
ROK vs CTXR
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.